PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

darunavir Side Effects

The reactions most often reported to the FDA for darunavir (also sold as Prezista), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

14,896
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2006 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of darunavir come from 14,896 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 14,896 reports to the FDA Adverse Event Reporting System (FAERS) for darunavir (Prezista): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

14,896

Reports Mentioning Death

1,479

9.9% of reports — not proof the medicine caused the death

Hospitalizations

4,607

30.9% of reports

Top Indication

Hiv Infection

Most Reported Adverse Reactions

FOETAL EXPOSURE DURING PREGNANCY
1,150
DRUG INTERACTION
981
PAIN
889
EMOTIONAL DISTRESS
812
ANXIETY
811
ANHEDONIA
704
CHRONIC KIDNEY DISEASE
569
EXPOSURE DURING PREGNANCY
565
MATERNAL EXPOSURE DURING PREGNANCY
535
DIARRHOEA
497
RENAL FAILURE
497
DEATH
496
ACUTE KIDNEY INJURY
485
VIROLOGIC FAILURE
474
OSTEOPOROSIS
436
DEPRESSION
431
DRUG RESISTANCE
418
RENAL IMPAIRMENT
406

Who Reports Side Effects

Gender Distribution

Female 4,316 (36%)
Male 7,660 (63%)
Unknown 151

Age Distribution

0-17 598 (7%)
18-44 3,286 (38%)
45-64 4,091 (47%)
65-74 563 (6%)
75+ 174 (2%)

Reporting Trend by Year

2006 2025

Reactions in Death Reports

Top reactions reported in 1,479 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 493
FOETAL EXPOSURE DURING PREGNANCY 177
TREATMENT FAILURE 112
DRUG RESISTANCE 98
CD4/CD8 RATIO DECREASED 96
CD4 LYMPHOCYTES DECREASED 84
CARDIAC ARREST 59
DRUG INTERACTION 54
PNEUMONIA 54
DIARRHOEA 53
RENAL FAILURE 50
ANAEMIA 42
COMPLETED SUICIDE 42
HEART DISEASE CONGENITAL 40
RESPIRATORY FAILURE 40
HYPOTENSION 39
ANXIETY 38
TOXICITY TO VARIOUS AGENTS 37
ACUTE KIDNEY INJURY 36

Reactions in Hospitalization Reports

Top reactions in 4,607 reports where hospitalization was an outcome.

Reaction Reports
DRUG INTERACTION 385
ACUTE KIDNEY INJURY 318
PAIN 260
ANXIETY 235
RENAL FAILURE 234
EMOTIONAL DISTRESS 229
PYREXIA 225
DIARRHOEA 217
ANHEDONIA 202
NAUSEA 180
ANAEMIA 171
CHRONIC KIDNEY DISEASE 168
RENAL IMPAIRMENT 151
RASH 137
VOMITING 137
ASTHENIA 135
HOSPITALISATION 133
PNEUMONIA 132
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 131

Compare darunavir vs acyclovir →

What the FAERS Data Reveals About darunavir Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 14,896 voluntary reports linked to darunavir and its brand equivalents (Prezista), spanning 2006 through 2025. Of those, 1,479 (9.9%) listed death as an outcome and 4,607 (30.9%) involved hospitalization. The most common indication reported alongside adverse events was Hiv Infection.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 36% were female and 63% male; age distribution skews toward 45-64, with 4,091 reports in that bracket. The single most reported reaction is foetal exposure during pregnancy with 1,150 submissions, followed by drug interaction and pain.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.